Adherence to extended release tolterodine versus immediate- and extended-release oxybutynin among commercially-insured patients with overactive bladder

被引：0
|
作者：
Ollendorf, DA
Jumadilova, Z
Varadharajan, S
Girase, P
机构：
[1] Pharmetrics, Watertown, MA USA
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)63137-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [41] A cost effectiveness analysis of solifenacin compared with extended-release tolterodine for the treatment of overactive bladder
    Kang, H. H.
    Bae, J. Y.
    Park, S. Y.
    Sohn, H. S.
    VALUE IN HEALTH, 2007, 10 (06) : A319 - A319
  • [42] Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence
    Roehrborn, Claus G.
    Abrams, Paul
    Rovner, Eric S.
    Kaplan, Steven A.
    Herschorn, Sender
    Guan, Zhonghong
    BJU INTERNATIONAL, 2006, 97 (05) : 1003 - 1006
  • [43] Immediate- vs extended-release metoprolol in heart failure
    Huneycutt, B
    JOURNAL OF FAMILY PRACTICE, 2003, 52 (08): : 635 - 636
  • [44] Oxybutynin Extended Release and Tolterodine Immediate ReleaseA Health Economic Comparison
    D. Getsios
    J. J. Caro
    K. J. Ishak
    W. El-Hadi
    K. Payne
    M. O’Connel
    D. Albrecht
    W. Feng
    D. Dubois
    Clinical Drug Investigation, 2004, 24 : 81 - 88
  • [45] Once-daily solifenacin succinate or extended-release tolterodine for overactive bladder syndrome?
    Jean Jacques Wyndaele
    Nature Clinical Practice Urology, 2006, 3 : 184 - 185
  • [46] Once-daily solifenacin succinate or extended-release tolterodine for overactive bladder syndrome?
    Wyndaele, JJ
    NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (04): : 184 - 185
  • [47] Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study
    Appell, RA
    Sand, P
    Dmochowski, R
    Anderson, R
    Zinner, N
    Lama, D
    Roach, M
    Miklos, J
    Saltzstein, D
    Boone, T
    Staskin, DR
    Albrecht, D
    MAYO CLINIC PROCEEDINGS, 2001, 76 (04) : 358 - 363
  • [48] Health-related quality of life in patients with overactive bladder receiving tolterodine extended-release in Japan
    Homma, Y
    Kawabe, KK
    JOURNAL OF UROLOGY, 2003, 169 (04): : 345 - 345
  • [49] Oxybutynin extended release for the management of overactive bladder: a clinical review
    Arisco, A. M.
    Brantly, E. K.
    Kraus, S. R.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2009, 3 : 151 - 161
  • [50] Dose and duration of use among commercially insured adults prescribed immediate-release (IR) or extended-release (ER) oxycodone
    DeVeaugh-Geiss, Angela
    Coplan, Paul
    Kadakia, Aditi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 130 - 130
12345